The global isoxazoline drugs market size was valued at USD 6.1 billion in 2025 and is projected to grow from USD 6.99 billion in 2026 to USD 20.79 billion by 2034 at a CAGR of 14.6% during the forecast period 2026-2034.
Isoxazoline class of drugs are oral insecticides that received a license for ectoparasite treatment in companion animals such as dogs and cats. These drugs were first launched in 2013 as veterinary drugs against ticks and fleas in dogs. However, several studies have shown their efficiency against other veterinary and agricultural parasites. FDA-approved products in the isoxazoline drugs class are Bravecto, Credlio, Nexgard, and Simparica.
The US FDA approves these drugs for tick and flea infestation. Some of them are also approved for treating gastrointestinal parasite infections and controlling ear mites. These drugs are ingested or applied topically. Most active ingredients were introduced for crop protection and later for companion animals.
Innovations on the existing drugs for new indications in oral and topical formulations and growing awareness for ectoparasites prevention and control of fleas and ticks, are likely to augment the market growth. The market is segmented into product type, pet type, and region.
Download Free Sample Report To learn more about this report,
In recent years, a surge in the expenditure on pet animal care has been noted. According to the American Pet Products Association, Inc. (APPA), "Total of USD 97.1 billion was US Pet Industry Expenditure in 2019. Similarly, in 2020, USD 103.6 billion was the US Pet Industry Expenditure. In 2020, USD 31.4 billion was spent on vet care and product sales, and approximately USD 32.2 billion was estimated to be spent in 2021."
Ticks and fleas commonly infest companion animals such as dogs and cats. Several commercially available drugs help prevent and control ticks and flea infestations among dogs and cats. Isoxazoline being among the new class of ectoparasite drugs for dogs and cat,s has growing demand in the market. Increasing expenditure on pet care and the rising adoption of pets is the primary factors propelling the demand for isoxazoline drugs.
Several products are available in the market to prevent and control ticks and fleas. Some of these products are regulated by the Environmental Protection Agency and the US FDA. The US Food and Drug Administration considers these products safe and effective in cats and dogs. However, isoxazoline drugs need to be approved by the US FDA, EMA, and Canada Health to be used on animals.
Drug manufacturers are conducting surveys among pet owners and veterinarians related to the use and safety of isoxazoline drugs. According to these surveys, it was noted that isoxazoline neurotoxicity was not ticks and flea specific. Post these surveys, the manufacturers have updated the labels for these drugs. However, the US FDA considers isoxazoline drugs safe and effective for cats and dogs.
Companies are investing in research for the API already available in the market for new indications. Through this, they will be able to expand the application of isoxazoline drugs in the market. For instance, in October 2019, Boehringer Ingelheim announced that the European Medicines Agency (EMA) granted them additional marketing authorization for new indications for NexGard and NexGard SPECTRA. These were indicated for fighting 8 species of ticks that afflict dogs. The latest indications are against the Ixodes hexagonus tick, most commonly reported in Europe.
Request Customizationto receive a tailored report.
The global isoxazoline drugs market is segmented into fluralaner, sarolaner, lotilaner, and afoxolaner based on product type. Afoxolaner type of drug had higher sales than the other drugs available in the market and held the largest market share in 2021.
Based on pet type, the market is categorized into dogs and cats. The adoption rate of dogs and cats surged during 2020–2021. According to a survey conducted by the Humane Society of the United States, nearly 45% of the household in the US owns at least one dog. In 2021, the dogs' segment acquired the majority of the share and is expected to grow at a CAGR of 18.11% during the forecast period.
Speak to an Analystto discuss market opportunities.
North America acquired the largest share of the isoxazoline drugs market in 2021 and a CAGR of 16.8% during the forecast period. The highest number of drug approvals and a higher adoption rate are among the major factors contributing to the growth of the market.
Asia-Pacific is anticipated to hold the highest market share in the isoxazoline drugs market. The rising adoption rate in countries such as India and China and growing awareness of pet care among the population are anticipated to propel the market during the projected period. Growing expenditure for pet care in India is likely to provide booming opportunities. According to the Indian Federation of Animal Health Companies, "the Indian animal healthcare market is estimated to be around Rs. 5,500 crores (USD 770 million) (2020).”
Approximately 5% of the animal healthcare expenditure is spent on companion animals. The lack of isoxazoline manufacturers in these regions also presents an opportunity for well-established players. Moreover, companies are targeting to get the approval of their drugs in India and China. Such factors are anticipated to provide great opportunities to the manufacturers for expanding their reach in these developing countries.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com